Abbot Laboratories completed an application with the FDA to seek U.S. market approval for its latest coronary stent system.
Abbot, based in Illinois, operates a research facility in Worcester.
The company’s XIENCE V Everolimus Eluting Coronary Stent System was launched in Europe and the Asia/Pacific region in 2006. It uses everolimus, a drug shown to effectively prevent coronary “re-narrowing” following stent applications, the company said.
In clinical trials, the Abbot stent was proven more effective than a major competitor’s product, the company said.
